SNN

Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Smith & Nephew plc (SNN) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.3 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
B+
Factor Score 3.6 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 21.3
EV / EBITDA 50.4
Rev Growth YoY 4.6%
Gross Margin 68.4%
Price Return 3M 6.6%
Price Return 12M -4.0%
Catalyst Signal 0.00
Market Cap $13.1B
TTM Revenue $6.3B
Price / Sales 2.1
ROE 11.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C (2.3) C- (2.1) B+ (3.6) B- (3.1) C+ (2.6) C+ (2.7)
2026-11-08 C (2.2) C- (2.1) B+ (3.6) C+ (2.8) C+ (2.6) C+ (2.7)
2026-11-01 C (2.4) C- (2.0) B+ (3.6) C (2.4) F (0.0) C- (2.1)
2026-10-25 C (2.4) C- (2.0) B+ (3.6) C (2.3) F (0.0) C- (2.1)
2026-10-18 C (2.4) C- (2.0) B+ (3.6) C (2.3) F (0.0) C- (2.1)
Page 1 of 3